|
Volumn 160, Issue 20, 2000, Pages 3114-3120
|
Differential access in the receipt of antiretroviral drugs for the treatment of aids and its implications for survival
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
DEAVIRDINE;
DIDANOSINE;
INDINAVIR;
LAMIVUDINE;
NELFINAVIR;
NEVIRAPINE;
NUCLEOSIDE ANALOG;
PROTEINASE INHIBITOR;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SAQUINAVIR;
STAVUDINE;
UNCLASSIFIED DRUG;
ZALCITABINE;
ZIDOVUDINE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ADULT;
ANALYTIC METHOD;
ARTICLE;
CAUCASIAN;
CONTROLLED STUDY;
DIAGNOSTIC APPROACH ROUTE;
DRUG EFFICACY;
DRUG UTILIZATION;
ETHNIC GROUP;
FEMALE;
HEALTH CARE ACCESS;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MEDICAID;
MORTALITY;
NEGRO;
PRIORITY JOURNAL;
RACE DIFFERENCE;
RISK FACTOR;
SEX DIFFERENCE;
SOCIOECONOMICS;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 0034645476
PISSN: 00039926
EISSN: None
Source Type: Journal
DOI: 10.1001/archinte.160.20.3114 Document Type: Article |
Times cited : (63)
|
References (22)
|